when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Small Molecule · news · pharmadog

← back to Small Molecule

News · Small Molecule

466 stories

Aug 20, 26Chutes & Ladders—Neumora shuffles leadership ahead of INDfiercebiotech

Aug 20, 26Contrasting legal decisions on gender-affirming carestat

Aug 19, 26STAT+: Pharmalittle: We’re reading about an FDA commish nominee, mRNA cancer vaccine results, and morestat

Aug 19, 26Enveda’s exercise-simulating obesity tablet clears early clinical testbiospace

Aug 19, 26Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, morebiospace

Aug 19, 26Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?biospace

Aug 18, 26AstraZeneca scores in lung cancer; Sandoz inks a China dealbiopharma dive

Aug 18, 26Leo Pharma buys rare skin disease drug in $435M dealbiopharma dive

Aug 18, 26LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drugbiospace

Aug 18, 26STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle massstat

Aug 18, 26BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZenecafiercebiotech

Aug 18, 26Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposureendpoints

Aug 17, 26Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodfiercebiotech

Aug 14, 26STAT+: PBMs agree to display TrumpRx drug pricesstat

Aug 14, 26STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and morestat

Aug 14, 26STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug classstat

Aug 14, 26‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryfiercebiotech

Aug 13, 26STAT+: Eli Lilly targets booming black market for retatrutidestat

Aug 13, 26Chutes & Ladders—Former Legend CEO lands at K2fiercebiotech

Aug 13, 26STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and morestat

Aug 13, 26Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contestendpoints

Aug 13, 26Behind the bell: Gearing up to go publicbiospace

Aug 13, 26Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalfiercebiotech

Aug 12, 26Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pillfiercebiotech

Aug 12, 26Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readoutbiospace

Aug 12, 26Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesbiopharma dive

Aug 12, 26Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease assetbiospace

Aug 12, 26Definium's LSD drug clears bar in first of two Phase 3 anxiety disorder trialsendpoints

Aug 12, 26Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlightbiospace

Aug 11, 26Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxietyfiercebiotech

← prevpage 6 of 16next →